Aclaris Therapeutics, Inc.

ACRSNASDAQ • USD
3.61 USD
↘ 0.32 (8.04%)AT CLOSE (03:59 PM EST)
3.63
↗ 0.02 (0.69%)
POST MARKET (AS OF 07:30 PM EST)
Post Market
AS OF 07:30 PM EST
3.63
↗ 0.02 (0.69%)
🔴Market: CLOSED

ACRS is currently priced at $3.60. Both sides of the analysis point lower: technicals flash "Strong Sell" and fundamentals confirm with a "Sell" reading. Key drivers include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 2/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Furthermore, ACRS is currently richly valued, trading at a premium to sector peers across key valuation metrics.

Technical & fundamental data as of Nov 16, 2026.

Open?$3.38
High?$3.70
Low?$3.28
Prev. Close?$3.92
Volume?10.0M
Avg. Volume?3.3M
VWAP?$3.53
Rel. Volume?2.97x
Bid / Ask
Bid?$3.25 × 600
Ask?$3.65 × 100
Spread?$0.40
Midpoint?$3.45
Valuation & Ratios
Market Cap?572.6M
Shares Out?158.6M
Float?108.7M
Float %?77.7%
P/E Ratio?N/A
P/B Ratio?3.43
EPS?-$0.50
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
Employees
73
Market Cap
621.8M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2015-10-07
Address
701 LEE ROAD
WAYNE, PA 19087
Phone: 484-324-7933
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
12
Z-Score?
1
Momentum?
40
Short Sent.?
50
Piotroski F-Score?2/9Weak
Altman Z-Score?-0.50Distress
Confidence?63%Moderate
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?10.65%High
Short Interest?11.6M
Days to Cover?4.0
Free Float108.7M
Avg Daily Volume2.9M
Settlement Date2026-10-30
Financial Health
Current Ratio?5.09Strong
Quick Ratio?5.09Strong
Cash Ratio?0.84Adequate
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
58/100
P/E?
N/A▾
P/B?
Peers
100
S&P
50
3.43FAIR▾
P/S?
Peers
100
S&P
3
89.45HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-6.2CHEAP▾
EV/Sales?
Peers
100
S&P
3
86.27HIGH▾
Returns & Efficiency
ROE?
S&P
3
-47.7%WEAK▾
ROA?
S&P
3
-36.8%WEAK▾
Cash Flow & Enterprise
FCF?$-75315000
Enterprise Value?$552.2M
Fundamentals ratios updated end of day